CTOs on the Move

Sobi North America

www.sobi-northamerica.com

 
Sobi is an international specialty healthcare company dedicated to developing treatments and extensive patient support networks for people with rare and difficult to treat diseases. These patients are often misunderstood, misdiagnosed and have limited medical options otherwise. This commitment has led to our world-class capabilities in protein biochemistry and biologics manufacturing, recognized by our leading industry partners.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Vidacare Corporation

Vidacare Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in San Antonio, TX. To find more information about Vidacare Corporation, please visit www.vidacare.com

Dental Art Laboratory Inc

Dental Art Laboratory Inc is a Lansing, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Epilepsy Society

American Epilepsy Society is a West Hartford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.

ConnectiCare

ConnectiCare is a leading health plan in the state of Connecticut. ConnectiCare has been dedicated to making Connecticut a healthier place to live and work since the company was founded in 1981. ConnectiCare has a full range of products and services for businesses, municipalities, individuals, and those who are Medicare-eligible. ConnectiCare is part of the EmblemHealth family of companies.